A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient
Status:
Recruiting
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This is a Multicentre, Open-label, single-arm, Phase II Study to Evaluate the Safety and
Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic Anemia.
55 adult patients with SAA will be enrolled in the study. Treatment with Hetrombopag will be
started at 7.5 mg/day and uptitrated according to the platelet count. The primary objective
of the study is to assess the safety and efficacy of Hetrombopag in patients with SAA.